Groupama Asset Managment Takes Position in Edwards Lifesciences Corporation $EW

Groupama Asset Managment bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 17,203 shares of the medical research company’s stock, valued at approximately $1,338,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of EW. JPL Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at about $25,000. True Wealth Design LLC grew its position in shares of Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares in the last quarter. Rakuten Securities Inc. increased its stake in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after buying an additional 302 shares during the period. Hantz Financial Services Inc. increased its stake in shares of Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after buying an additional 164 shares during the period. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in Edwards Lifesciences in the third quarter valued at approximately $30,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total value of $1,103,960.00. Following the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at $3,371,239.08. This trade represents a 24.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $85.93, for a total transaction of $974,446.20. Following the completion of the transaction, the vice president directly owned 21,266 shares in the company, valued at $1,827,387.38. This represents a 34.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 61,718 shares of company stock valued at $5,236,281 over the last three months. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $82.52 on Friday. The stock has a market capitalization of $47.92 billion, a PE ratio of 45.09, a price-to-earnings-growth ratio of 2.15 and a beta of 0.93. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The stock’s 50-day moving average price is $82.23 and its 200 day moving average price is $81.64. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. During the same period in the previous year, the business posted $0.59 earnings per share. The firm’s revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Truist Financial set a $89.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Royal Bank Of Canada raised their price objective on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, December 5th. Wells Fargo & Company lifted their price objective on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Citigroup reiterated a “buy” rating and set a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Finally, Canaccord Genuity Group set a $87.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, December 17th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.